Latest Health News

Vitura Health Limited reported an 8.3% rise in half-year revenues to $67.87 million, driven by medicinal cannabis sales and telehealth services, yet posted a consolidated loss of $986,341 due to margin pressures and increased costs. Leadership changes and strategic investments mark a pivotal phase for the digital health and medicinal cannabis player.

Anatara Lifesciences reports a significantly reduced net loss for H1 FY2026, driven by promising pre-clinical results in its anti-obesity program and a successful $1.2 million capital raise. The company also highlights positive Phase II trial outcomes for its gastrointestinal health product GaRP.

FINEOS Corporation Holdings Plc reported a modest revenue increase for 2025 but swung to a significant net loss, raising questions about its financial trajectory.

Advanced Braking Technology Ltd reported a robust 27.2% revenue increase and a 61.6% rise in net profit for H1 2026, driven by strong international sales and progress in autonomous braking technology.

Amplitude Energy has delivered a standout half-year performance with record gas production and a 246% jump in profit, while advancing key projects and strengthening its balance sheet.

Doctor Care Anywhere has reported its first profitable year, driven by a 6.5% revenue growth and improved margins, setting the stage for accelerated growth in 2026. The telehealth provider reaffirms ambitious medium-term targets amid operational enhancements and new clinical pathways.

Bapcor Limited has postponed its half-year financial results release to no later than 27 February 2026 and is seeking an extension of its trading suspension, hinting at a potential capital raising.

TrivarX Limited reported a $1.26 million half-year loss as it completed the acquisition of Stabl-Im brain imaging IP and validated its mental health screening technology in veterans. The company raised $4.2 million to fund clinical development and expand its diagnostic portfolio.

Scentre Group has reported a robust 2025 financial year with Funds From Operations rising 4.9% and distributions up 3.4%, underpinned by record occupancy and strong customer engagement. The Group also advanced its sustainability agenda, exceeding interim net zero targets and progressing major redevelopment projects.

Radiopharm Theranostics has initiated dosing in its Phase 1/2a clinical trial of BetaBart, a novel radiotherapeutic developed with MD Anderson Cancer Center, targeting aggressive solid tumors.

Tasmea Limited posted a robust 62.4% revenue increase to $400.5 million in H1 FY26, alongside a 32.2% rise in underlying profit after tax, despite a dip in statutory net profit. The acquisition of WorkPac Group marks a strategic expansion into workforce solutions.

Integral Diagnostics Limited has reported a robust half-year performance, with revenues soaring 55.6% and EBITDA nearly doubling, driven by strong patient volume growth and successful integration of Capitol Health. The company also declared a fully franked interim dividend of 3.3 cents per share.